US Pharma and Biotech Summit

2024 is a pivotal year for US healthcare, in particular for the pharma and biotech industries. A presidential election will influence crucial policies on drug pricing and health financing for years to come. AI technologies are evolving from buzzwords to making an impact in drug R&D. Pharma is facing a huge patent cliff. And the biotech market appears to be pulling out of a slump just as the US economy executes the soft landing policymakers have hoped for.

The Financial Times US Pharma and Biotech Summit returned to New York in May 2024, partnered with Endpoints News for the first time. The event gathered biopharma leaders, regulators, investors and scientists to share unique insights about the year ahead and discuss the most important trends affecting the industry, and the country.  

In May attendees learnt how the new market cycle will finance the next period of investing in innovation. They debated the dueling approaches to the US life expectancy crisis, and heard how artificial intelligence is splitting into two technological camps. As well as learnt how drug makers, tech startups and insurers are fighting it out to redefine their relationship with patients. 

Investment

Where are investors in American life sciences putting their money? How is competitiveness across the biopharma industry evolving? What challenges do biotech leaders face in negotiating partnerships and potentially acquisition?

Innovation

How far has the application of AI in life sciences come in the last year and what breakthroughs could be coming? What new skills and solutions are young pharma professionals bringing to workforces and how are they driving innovation? 

Policy

What should the biopharma industry expect in terms of economic policy, and how will those macro dynamics affect business and investment trends? What could be the impact of a pivotal presidential election on the industry? 

Learn

how America's life sciences landscape is evolving in areas such as innovation, commercialization and regulation

Engage

with C-suite executives responsible for the big decisions in areas such as funding, workforce development and strategic partnerships

Enjoy

the opportunity to network with peers and build relationships in a friendly but focused environment

Obesity Drugs: Market Dynamics and Growth Potential

Explore our industry report addressing the worldwide obesity epdidemic and the explosion in demand fueling innovation and investment.

Event Brochure

Download an overview of the key topics, confirmed speakers and examples of companies you could be meeting in-person and online.

The power of in-person networking

• Engage with senior executives from prominent life sciences companies, CROs and healthcare providers 
  
  
• 75% of attendees in 2023 had a job title of 'Head of' or above, so true decision-makers will be on site 
  
  
• Schedule 1-to-1 meetings with leaders in the online event community 
  
  
• Establish new relationships and strengthen ties at our evening drinks reception 
  
  
• FT editors and other global press outlets will be there 

Global Pharma and Biotech Summit

5 - 7 November 2024

In-Person & Digital
London

Speaking Opportunities

Ciaran Larkin
ciaran.larkin@ft.com

Sponsorship

Holly Watson-Steward
holly.watson-steward@ft.com  

Delegate Services 

Hauwra Sharif
hauwra.sharif@ft.com 

© Financial Times Live

FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice